Close Menu

Tissue-Based Testing

News on immunohistochemistry and other tissue-based testing methods.

The aim of the study is to establish a tumor registry based on blood and bone marrow samples from cancer patients with linked outcomes data, which the firm can use for precision drug development.

Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.

The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.

The firm hopes for a decision from the FDA later this year for its breast cancer drug candidate alpelisib, following results from a late-stage trial.

Kiyatec's cell-based assays model and predict patient therapeutic response to drive cancer drug development and potentially guide treatment.